{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:43:06Z","timestamp":1793846586016,"version":"4.6.1"},"reference-count":310,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.pharmthera.2025.108862","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T19:06:02Z","timestamp":1745262362000},"page":"108862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Retina-directed gene therapy: Achievements and remaining challenges"],"prefix":"10.1016","volume":"271","author":[{"given":"Josef","family":"Biber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Gandor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvir","family":"Becirovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Michalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb0005","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1167\/iovs.17-22978","article-title":"Concepts and strategies in retinal gene therapy","volume":"58","author":"Aguirre","year":"2017","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0010","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cell.2015.03.023","article-title":"Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis","volume":"161","author":"A\u00eft-Ali","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2020.107912","article-title":"Dual and triple AAV delivery of large therapeutic gene sequences into the inner ear","volume":"394","author":"Akil","year":"2020","journal-title":"Hearing Research"},{"issue":"7\u20138","key":"10.1016\/j.pharmthera.2025.108862_bb0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41434-024-00455-z","article-title":"Retinoic acid related orphan receptor \u03b1 is a genetic modifier that rescues retinal degeneration in a mouse model of Stargardt disease and Dry AMD","volume":"31","author":"Akula","year":"2024","journal-title":"Gene Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41592-020-0966-x","article-title":"An efficient KRAB domain for CRISPRi applications in human cells","volume":"17","author":"Alerasool","year":"2020","journal-title":"Nature Methods"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108862_bb0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm1596","article-title":"Restoration of cone vision in a mouse model of achromatopsia","volume":"13","author":"Alexander","year":"2007","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0035","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1172\/JCI34316","article-title":"Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice","volume":"118","author":"Allocca","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0045","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo","volume":"42","author":"An","year":"2024","journal-title":"Nature biotechnology"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2024.108349","article-title":"Inteins: A Swiss army knife for synthetic biology","volume":"73","author":"Anastassov","year":"2024","journal-title":"Biotechnology Advances"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Progress in Retinal and Eye Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0060","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","article-title":"Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing","volume":"40","author":"Anzalone","year":"2022","journal-title":"Nature Biotechnology"},{"issue":"7785","key":"10.1016\/j.pharmthera.2025.108862_bb0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0070","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"Biodrugs"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0075","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: Poised at the clinical crossroads","volume":"20","author":"Asokan","year":"2012","journal-title":"Molecular Therapy: The journal of the American Society of Gene Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0080","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.exer.2010.07.017","article-title":"The inhibitor of phagocytosis, O-phospho-L-serine, suppresses M\u00fcller glia proliferation and cone cell regeneration in the light-damaged zebrafish retina","volume":"91","author":"Bailey","year":"2010","journal-title":"Experimental Eye Research"},{"issue":"20","key":"10.1016\/j.pharmthera.2025.108862_bb0085","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber\u2019s congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0090","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV capsid to evade immune responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Current Opinion in Biotechnology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108862_bb0100","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1128\/JVI.74.6.2777-2785.2000","article-title":"Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors","volume":"74","author":"Bartlett","year":"2000","journal-title":"Journal of Virology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00018-022-04175-8","article-title":"Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications","volume":"79","author":"Becirovic","year":"2022","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb0110","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/gt.2010.56","article-title":"rAAV2\/5 gene-targeting to rods:Dose-dependent efficiency and complications associated with different promoters","volume":"17","author":"Beltran","year":"2010","journal-title":"Gene Therapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090390","article-title":"Canine retina has a primate fovea-like bouquet of cone photoreceptors which is affected by inherited macular degenerations","volume":"9","author":"Beltran","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0120","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","article-title":"CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi","volume":"31","author":"Bendixen","year":"2023","journal-title":"Molecular Therapy"},{"issue":"7917","key":"10.1016\/j.pharmthera.2025.108862_bb0125","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41586-022-04877-w","article-title":"Compatibility rules of human enhancer and promoter sequences","volume":"607","author":"Bergman","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2006.02.026","article-title":"Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration","volume":"50","author":"Bi","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-024-03045-3","article-title":"Gliosis-dependent expression of complement factor H truncated variants attenuates retinal neurodegeneration following ischemic injury","volume":"21","author":"Biber","year":"2024","journal-title":"Journal of Neuroinflammation"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1096\/fj.05-4737fje","article-title":"Plasmid electrotransfer of eye ciliary muscle: Principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis","volume":"20","author":"Bloquel","year":"2006","journal-title":"FASEB Journal\u202f: Official Publication of the Federation of American Societies for Experimental Biology"},{"issue":"34","key":"10.1016\/j.pharmthera.2025.108862_bb0145","doi-asserted-by":"crossref","first-page":"eaba5614","DOI":"10.1126\/sciadv.aba5614","article-title":"A gene therapy for inherited blindness using dCas9-VPR-mediated transcriptional activation","volume":"6","author":"B\u00f6hm","year":"2020","journal-title":"Science Advances"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb0150","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.drudis.2019.05.038","article-title":"Ocular gene therapies in clinical practice: Viral vectors and nonviral alternatives","volume":"24","author":"Bordet","year":"2019","journal-title":"Drug Discovery Today"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0155","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ymthe.2020.02.009","article-title":"Pre-arrayed Pan-AAV peptide display libraries for rapid single-round screening","volume":"28","author":"B\u00f6rner","year":"2020","journal-title":"Molecular Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0160","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(85)80025-8","article-title":"A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus","volume":"41","author":"Boshart","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100975","article-title":"Early and late stage gene therapy interventions for inherited retinal degenerations","volume":"86","author":"Botto","year":"2022","journal-title":"Progress in Retinal and Eye Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0170","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1089\/hum.2012.125","article-title":"The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina","volume":"23","author":"Boye","year":"2012","journal-title":"Human Gene Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0175","first-page":"2791","article-title":"Protection against vision loss by ANX007: Results from the phase 2 ARCHER clinical trial","volume":"65","author":"Boyer","year":"2024","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"3 Pt 1","key":"10.1016\/j.pharmthera.2025.108862_bb0180","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1523\/JNEUROSCI.14-03-01030.1994","article-title":"GFAP promoter directs astrocyte-specific expression in transgenic mice","volume":"14","author":"Brenner","year":"1994","journal-title":"The Journal of neuroscience\u202f: the official journal of the Society for Neuroscience"},{"issue":"6865","key":"10.1016\/j.pharmthera.2025.108862_bb0185","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108862_bb0190","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41587-020-00793-4","article-title":"Deep diversification of an AAV capsid protein by machine learning","volume":"39","author":"Bryant","year":"2021","journal-title":"Nature Biotechnology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124197","article-title":"Recombinant adeno-associated viral vectors (rAAV)-vector elements in ocular gene therapy clinical trials and transgene expression and bioactivity assays","volume":"21","author":"Buck","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0205","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-1-61779-370-7_12","article-title":"Modification and labeling of AAV vector particles","volume":"807","author":"B\u00fcning","year":"2011","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0210","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid modifications for targeting and improving the efficacy of AAV vectors","volume":"12","author":"B\u00fcning","year":"2019","journal-title":"Molecular Therapy. Methods & Clinical Development"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0215","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","article-title":"The lancet Global Health Commission on global eye health: Vision beyond 2020","volume":"9","author":"Burton","year":"2021","journal-title":"The Lancet. Global Health"},{"issue":"5990","key":"10.1016\/j.pharmthera.2025.108862_bb0220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.1190897","article-title":"Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa","volume":"329","author":"Busskamp","year":"2010","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0225","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1172\/JCI65654","article-title":"Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration","volume":"125","author":"Byrne","year":"2015","journal-title":"The Journal of Clinical Investigation"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0230","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135112","article-title":"In vivo-directed evolution of adeno-associated virus in the primate retina","volume":"5","author":"Byrne","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318452","article-title":"Treatments for dry age-related macular degeneration: Therapeutic avenues, clinical trials and future directions","volume":"106","author":"Cabral de Guimaraes","year":"2022","journal-title":"The British Journal of Ophthalmology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0240","doi-asserted-by":"crossref","first-page":"eaav3335","DOI":"10.1126\/sciadv.aav3335","article-title":"In vivo genome editing rescues photoreceptor degeneration via a Cas9\/RecA-mediated homology-directed repair pathway","volume":"5","author":"Cai","year":"2019","journal-title":"Science Advances"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb0245","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clinical and Vaccine Immunology: CVI"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0250","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"The Journal of Infectious Diseases"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb0255","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41592-019-0508-6","article-title":"Multiplexed genome engineering by Cas12a and CRISPR arrays encoded on single transcripts","volume":"16","author":"Campa","year":"2019","journal-title":"Nature Methods"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0260","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases","volume":"49","author":"Campochiaro","year":"2015","journal-title":"Progress in Retinal and Eye Research"},{"issue":"10436","key":"10.1016\/j.pharmthera.2025.108862_bb0265","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: A phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0270","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3389\/fnins.2017.00503","article-title":"Evaluating efficiencies of dual AAV approaches for retinal targeting","volume":"11","author":"Carvalho","year":"2017","journal-title":"Frontiers in Neuroscience"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb0275","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nature Neuroscience"},{"issue":"580","key":"10.1016\/j.pharmthera.2025.108862_bb0280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0285","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly efficient Cas9-mediated transcriptional programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nature Methods"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0290","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nmeth.3871","article-title":"Comparison of Cas9 activators in multiple species","volume":"13","author":"Chavez","year":"2016","journal-title":"Nature Methods"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0295","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1073\/pnas.91.7.2611","article-title":"The human blue opsin promoter directs transgene expression in short-wave cones and bipolar cells in the mouse retina","volume":"91","author":"Chen","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108862_bb0300","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0305","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41525-021-00180-1","article-title":"Genetic characteristics and epidemiology of inherited retinal degeneration in Taiwan","volume":"6","author":"Chen","year":"2021","journal-title":"NPJ Genomic Medicine"},{"issue":"23\u201324","key":"10.1016\/j.pharmthera.2025.108862_bb0310","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1089\/hum.2021.122","article-title":"Neutralizing antibody evasion and transduction with purified extracellular vesicle-enveloped adeno-associated virus vectors","volume":"32","author":"Cheng","year":"2021","journal-title":"Human Gene Therapy"},{"issue":"13\u201314","key":"10.1016\/j.pharmthera.2025.108862_bb0315","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/hum.2021.29167.syc","article-title":"Ocular inflammation with anti-vascular endothelial growth factor treatments","volume":"32","author":"Cheng","year":"2021","journal-title":"Human Gene Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0320","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"19","key":"10.1016\/j.pharmthera.2025.108862_bb0325","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1093\/hmg\/ddt320","article-title":"L-arginine:glycine amidinotransferase deficiency protects from metabolic syndrome","volume":"22","author":"Choe","year":"2013","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0330","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2014.8","article-title":"Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors","volume":"21","author":"Colella","year":"2014","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0335","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41587-024-02240-0","article-title":"Development of multiplexed orthogonal base editor (MOBE) systems","volume":"43","author":"Cowan","year":"2025","journal-title":"Nature Biotechnolog"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/genes9040215","article-title":"Special issue introduction: Inherited retinal disease: Novel candidate genes, genotype-phenotype correlations, and inheritance models","volume":"9","author":"Cremers","year":"2018","journal-title":"Genes"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb0345","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.15252\/emmm.201404077","article-title":"Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter","volume":"6","author":"Cronin","year":"2014","journal-title":"EMBO Molecular Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb0350","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: Initial findings from a phase I\/IIa trial by intravitreal delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Molecular Therapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb0355","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1136\/bjo-2022-321903","article-title":"Genetic treatment for autosomal dominant inherited retinal dystrophies: Approaches, challenges and targeted genotypes","volume":"107","author":"Daich Varela","year":"2023","journal-title":"The British Journal of Ophthalmology"},{"issue":"189","key":"10.1016\/j.pharmthera.2025.108862_bb0360","doi-asserted-by":"crossref","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0365","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"International Journal of Biomedical Science\u202f: IJBS"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0370","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","article-title":"Efficient prime editing in mouse brain, liver and heart with dual AAVs","volume":"42","author":"Davis","year":"2023","journal-title":"Nature Biotechnology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0375","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nature Biotechnology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0380","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the center of the cell: Tracing the path of AAV transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends in Molecular Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108862_bb0385","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","article-title":"Phage-assisted evolution and protein engineering yield compact, efficient prime editors","volume":"186","author":"Doman","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/mt.2009.258","article-title":"Characterization of genome integrity for oversized recombinant AAV vector","volume":"18","author":"Dong","year":"2010","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0395","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/mt.2011.69","article-title":"Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness","volume":"19","author":"Doroudchi","year":"2011","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0400","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/imr.13149","article-title":"Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway","volume":"313","author":"Dreismann","year":"2023","journal-title":"Immunological Reviews"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0405","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"Journal of Virology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0410","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/mthe.2001.0456","article-title":"Expanding AAV packaging capacity with trans-splicing or overlapping vectors: A quantitative comparison","volume":"4","author":"Duan","year":"2001","journal-title":"Molecular Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0415","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/75080","article-title":"A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation","volume":"6","author":"Duan","year":"2000","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0420","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02213-17","article-title":"An alternate route for adeno-associated virus (AAV) entry independent of AAV receptor","volume":"92","author":"Dudek","year":"2018","journal-title":"Journal of Virology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0425","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1089\/hum.2019.132","article-title":"Dual ABCA4-AAV vector treatment reduces pathogenic retinal A2E accumulation in a mouse model of autosomal recessive Stargardt disease","volume":"30","author":"Dyka","year":"2019","journal-title":"Human Gene Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0430","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/gt.2013.36","article-title":"Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization","volume":"20","author":"El Sanharawi","year":"2013","journal-title":"Gene Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0435","first-page":"2295","article-title":"GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD)","volume":"61","author":"Ellis","year":"2020","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"19","key":"10.1016\/j.pharmthera.2025.108862_bb0440","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0445","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01251-21","article-title":"Structurally mapping antigenic epitopes of adeno-associated virus 9: Development of antibody escape variants","volume":"96","author":"Emmanuel","year":"2022","journal-title":"Journal of Virology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101619","article-title":"Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases","volume":"5","author":"Esposito","year":"2024","journal-title":"Cell Reports Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108862_bb0455","doi-asserted-by":"crossref","first-page":"19064","DOI":"10.1074\/jbc.M309881200","article-title":"Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation","volume":"279","author":"Esumi","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0460","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0465","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1128\/jvi.70.1.520-532.1996","article-title":"Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis","volume":"70","author":"Fisher","year":"1996","journal-title":"Journal of Virology"},{"issue":"13\u201314","key":"10.1016\/j.pharmthera.2025.108862_bb0470","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1089\/hum.2020.070","article-title":"Engineered capsids for efficient gene delivery to the retina and cornea","volume":"31","author":"Frederick","year":"2020","journal-title":"Human Gene Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0475","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nature Genetics"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0480","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2174\/0113816128286593240226060318","article-title":"Machine-learning-guided directed evolution for AAV capsid engineering","volume":"30","author":"Fu","year":"2024","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0485","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene Neparvovec-rzyl for RPE65-mediated leber congenital amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmology Retina"},{"issue":"7681","key":"10.1016\/j.pharmthera.2025.108862_bb0490","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0495","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41467-023-42189-3","article-title":"Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina","volume":"14","author":"Gautam","year":"2023","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0500","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/14712598.2021.1856365","article-title":"RNA therapeutics for retinal diseases","volume":"21","author":"Gemayel","year":"2021","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb0505","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/gt.2016.66","article-title":"Development of an optimized AAV2\/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65","volume":"23","author":"Georgiadis","year":"2016","journal-title":"Gene Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/biology12020186","article-title":"AAV engineering for improving tropism to the central nervous system","volume":"12","author":"Ghauri","year":"2023","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0515","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jgm.835","article-title":"Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle","volume":"8","author":"Ghosh","year":"2006","journal-title":"The Journal of Gene Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0520","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/sj.mt.6300322","article-title":"A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner","volume":"16","author":"Ghosh","year":"2008","journal-title":"Molecular Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0525","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/hmg\/ddx438","article-title":"Cas9\/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery","volume":"27","author":"Giannelli","year":"2018","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0530","doi-asserted-by":"crossref","DOI":"10.1177\/25158414221134602","article-title":"RNA-based therapies in inherited retinal diseases","volume":"14","author":"Girach","year":"2022","journal-title":"Therapeutic Advances in Ophthalmology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0535","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41596-023-00875-y","article-title":"Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery","volume":"18","author":"Gonzalez","year":"2023","journal-title":"Nature Protocols"},{"issue":"1\u20134","key":"10.1016\/j.pharmthera.2025.108862_bb0540","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11068-008-9027-6","article-title":"eNpHR: A Natronomonas halorhodopsin enhanced for optogenetic applications","volume":"36","author":"Gradinaru","year":"2008","journal-title":"Brain Cell Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0545","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2217\/fvl.11.6","article-title":"Implications of the innate immune response to adenovirus and adenoviral vectors","volume":"6","author":"Gregory","year":"2011","journal-title":"Future Virology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb0550","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"Journal of Virology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075666","article-title":"Recombinant AAV-mediated BEST1 transfer to the retinal pigment epithelium: Analysis of serotype-dependent retinal effects","volume":"8","author":"Guziewicz","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.675897","article-title":"Challenges posed by immune responses to AAV vectors: Addressing root causes","volume":"12","author":"Hamilton","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109207","article-title":"Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering","volume":"35","author":"Hamilton","year":"2021","journal-title":"Cell Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0570","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: Challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Molecular Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0575","first-page":"866","article-title":"Comparative analysis of novel complement-targeted inhibitors, MiniFH, and the natural regulators factor H and factor H-like protein 1 reveal functional determinants of complement regulation","volume":"196","author":"Harder","year":"2016","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"9549","key":"10.1016\/j.pharmthera.2025.108862_bb0580","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis pigmentosa","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0585","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1525-0016(03)00012-1","article-title":"Generation and characterization of chimeric recombinant AAV vectors","volume":"7","author":"Hauck","year":"2003","journal-title":"Molecular Therapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0590","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF02150029","article-title":"Structure and composition of the inner limiting membrane of the retina. SEM on frozen resin-cracked and enzyme-digested retinas of Macaca mulatta","volume":"224","author":"Heegaard","year":"1986","journal-title":"Graefe\u2019s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb0595","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ophtha.2024.06.013","article-title":"Phase 1 study of JNJ-81201887 gene therapy in geographic atrophy secondary to age-related macular degeneration","volume":"131","author":"Heier","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.07.012","article-title":"Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer","volume":"342","author":"Herzog","year":"2019","journal-title":"Cellular Immunology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb0605","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/mt.2013.184","article-title":"Oversized AAV Transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway","volume":"21","author":"Hirsch","year":"2013","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0610","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41467-021-22404-9","article-title":"A systematic approach to inserting split inteins for Boolean logic gate engineering and basal activity reduction","volume":"12","author":"Ho","year":"2021","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108862_bb0615","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/BF01637091","article-title":"Intramural myocardial infarction under combined radiochemotherapy of an oesophageal carcinoma","volume":"116","author":"H\u00f6ring","year":"1990","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"7051","key":"10.1016\/j.pharmthera.2025.108862_bb0620","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nature03909","article-title":"Partial quantum information","volume":"436","author":"Horodecki","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0625","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/iovs.61.4.31","article-title":"In vivo CRISPR\/Cas9-mediated genome editing mitigates photoreceptor degeneration in a mouse model of X-linked retinitis pigmentosa","volume":"61","author":"Hu","year":"2020","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0630","first-page":"505","article-title":"Empowering retinal gene therapy with a specific promoter for human rod and cone ON-bipolar cells","volume":"17","author":"Hulliger","year":"2020","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/nano10020190","article-title":"Immunological and toxicological considerations for the design of liposomes","volume":"10","author":"Inglut","year":"2020","journal-title":"Nanomaterials"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: An overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0645","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1038\/s41467-023-38038-y","article-title":"Mini-PCDH15 gene therapy rescues hearing in a mouse model of Usher syndrome type 1F","volume":"14","author":"Ivanchenko","year":"2023","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0650","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41467-023-36217-5","article-title":"Multi-area recordings and optogenetics in the awake, behaving marmoset","volume":"14","author":"Jendritza","year":"2023","journal-title":"Nature Communications"},{"issue":"6096","key":"10.1016\/j.pharmthera.2025.108862_bb0655","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0660","first-page":"16","article-title":"Visual function restoration in a mouse model of Leber congenital amaurosis via therapeutic base editing","volume":"31","author":"Jo","year":"2023","journal-title":"Molecular Therapy: Nucleic acids"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0665","doi-asserted-by":"crossref","first-page":"eaax1210","DOI":"10.1126\/sciadv.aax1210","article-title":"CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis","volume":"5","author":"Jo","year":"2019","journal-title":"Science Advances"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb0670","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41593-019-0431-2","article-title":"Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans","volume":"22","author":"J\u00fcttner","year":"2019","journal-title":"Nature Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108862_bb0675","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0680","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1016\/j.ymthe.2023.09.019","article-title":"Preclinical evaluation of KH631, a novel rAAV8 gene therapy product for neovascular age-related macular degeneration","volume":"31","author":"Ke","year":"2023","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0685","first-page":"31","article-title":"Optogenetic targeting of AII amacrine cells restores retinal computations performed by the inner retina","author":"Khabou","year":"2023","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0690","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12967-024-05016-x","article-title":"Cell therapy for retinal degenerative disorders: A systematic review and three-level meta-analysis","volume":"22","author":"Khaboushan","year":"2024","journal-title":"Journal of Translational Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0695","first-page":"4356","article-title":"Interim results from the PRISM randomized phase 2 dose expansion trial evaluating 4D-150 in high anti-VEGF need individuals with neovascular (wet) age-related macular degeneration","volume":"65","author":"Khanani","year":"2024","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0700","doi-asserted-by":"crossref","DOI":"10.3390\/biom13101484","article-title":"Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center","volume":"13","author":"Kiraly","year":"2023","journal-title":"Biomolecules"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2025.108862_bb0705","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41434-023-00423-z","article-title":"Prednisolone and rapamycin reduce the plasma cell gene signature and may improve AAV gene therapy in cynomolgus macaques","volume":"31","author":"Kistner","year":"2024","journal-title":"Gene Therapy"},{"issue":"5720","key":"10.1016\/j.pharmthera.2025.108862_bb0710","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science (New York, N.Y.)"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0715","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/s41587-021-00938-z","article-title":"Efficient C\u2022G-to-G\u2022C base editors developed using CRISPRi screens, target-library analysis, and machine learning","volume":"39","author":"Koblan","year":"2021","journal-title":"Nature Biotechnology"},{"issue":"7603","key":"10.1016\/j.pharmthera.2025.108862_bb0720","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"7536","key":"10.1016\/j.pharmthera.2025.108862_bb0725","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14136","article-title":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex","volume":"517","author":"Konermann","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0730","article-title":"Directed evolution of AAV targeting primate retina by intravitreal injection identifies R100, a variant demonstrating robust gene delivery and therapeutic efficacy in non-human primates","author":"Kotterman","year":"2021","journal-title":"bioRxiv"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0735","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nature Reviews. Genetics"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0740","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates","volume":"22","author":"Kotterman","year":"2015","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0745","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.preteyeres.2015.05.001","article-title":"Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy","volume":"48","author":"Kowluru","year":"2015","journal-title":"Progress in Retinal and Eye Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0750","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaophthalmol.2022.6254","article-title":"Changes in retinal sensitivity associated with cotoretigene toliparvovec in X-linked retinitis pigmentosa with RPGR gene variations","volume":"141","author":"von Krusenstiern","year":"2023","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0755","first-page":"126","article-title":"Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108862_bb0760","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nn.2117","article-title":"Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration","volume":"11","author":"Lagali","year":"2008","journal-title":"Nature Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0765","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/mt.2009.256","article-title":"Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome or = 8.2 kb","volume":"18","author":"Lai","year":"2010","journal-title":"Molecular Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0770","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/nbt1153","article-title":"Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors","volume":"23","author":"Lai","year":"2005","journal-title":"Nature Biotechnology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0775","first-page":"406","article-title":"OCU400 nuclear hormone receptor-based gene modifier therapy: Safety and efficacy from phase 1\/2 clinical trial for retinitis pigmentosa associated with NR2E3 and RHO mutations","volume":"65","author":"Lam","year":"2024","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb0780","article-title":"In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR\/Cas9 in the mouse retina","volume":"5","author":"Latella","year":"2016","journal-title":"Molecular Therapy: Nucleic Acids"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0785","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Communications Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0790","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052456","article-title":"Current strategies for increasing knock-in efficiency in CRISPR\/Cas9-based approaches","volume":"25","author":"Leal","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0795","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jgm.1126","article-title":"Novel AAV serotypes for improved ocular gene transfer","volume":"10","author":"Lebherz","year":"2008","journal-title":"The Journal of Gene Medicine"},{"issue":"7991","key":"10.1016\/j.pharmthera.2025.108862_bb0805","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/d41586-023-03797-7","article-title":"CRISPR 2.0: A new wave of gene editors heads for clinical trials","volume":"624","author":"Ledford","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0810","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40291-024-00705-1","article-title":"In vivo LNP-CRISPR approaches for the treatment of hemophilia","volume":"28","author":"Lee","year":"2024","journal-title":"Molecular Diagnosis & Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0815","first-page":"161","article-title":"In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector","volume":"32","author":"Lee","year":"2023","journal-title":"Molecular Therapy: Nucleic Acids"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0820","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Experimental & Molecular Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108862_bb0825","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1016\/j.cub.2017.01.016","article-title":"Inteins","volume":"27","author":"Lennon","year":"2017","journal-title":"Current Biology: CB"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0830","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nature Biomedical Engineering"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb0835","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nature Reviews. Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0840","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0845","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/crispr.2017.0009","article-title":"Allele-specific CRISPR-Cas9 genome editing of the single-base P23H mutation for rhodopsin-associated dominant retinitis pigmentosa","volume":"1","author":"Li","year":"2018","journal-title":"The CRISPR Journal"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0850","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Molecular Vision"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0855","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.visres.2007.07.026","article-title":"Cone-specific expression using a human red opsin promoter in recombinant AAV","volume":"48","author":"Li","year":"2008","journal-title":"Vision Research"},{"issue":"13\u201314","key":"10.1016\/j.pharmthera.2025.108862_bb0860","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1089\/hum.2023.017","article-title":"Split AAV8 mediated ABCA4 expression for gene therapy of Mouse Stargardt Disease (STGD1)","volume":"34","author":"Li","year":"2023","journal-title":"Human Gene Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0865","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41434-020-0134-z","article-title":"Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa","volume":"28","author":"Li","year":"2021","journal-title":"Gene Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0870","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41525-024-00391-2","article-title":"Whole genome sequencing enables new genetic diagnosis for inherited retinal diseases by identifying pathogenic variants","volume":"9","author":"Liu","year":"2024","journal-title":"NPJ Genomic Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb0875","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/gt.2013.3","article-title":"Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus","volume":"20","author":"Lopes","year":"2013","journal-title":"Gene Therapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0880","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bjo-2022-321488","article-title":"Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy","volume":"107","author":"Lopez","year":"2023","journal-title":"The British Journal of Ophthalmology"},{"issue":"10441","key":"10.1016\/j.pharmthera.2025.108862_bb0885","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(23)02874-X","article-title":"AAV1-hOTOF gene therapy for autosomal recessive deafness 9: A single-arm trial","volume":"403","author":"Lv","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0890","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ymthe.2017.11.019","article-title":"Triple vectors expand AAV transfer capacity in the retina","volume":"26","author":"Maddalena","year":"2017","journal-title":"Molecular Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0895","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nmeth.2598","article-title":"CRISPR RNA-guided activation of endogenous human genes","volume":"10","author":"Maeder","year":"2013","journal-title":"Nature Methods"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb0900","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0905","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00018-019-03422-9","article-title":"The role of hypoxia-inducible factors in neovascular age-related macular degeneration: A gene therapy perspective","volume":"77","author":"Mammadzada","year":"2019","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0910","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nature Communications"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0915","first-page":"4491","article-title":"Optogenetics in the clinic: PIONEER, a phase 1\/2a gene therapy program for non-syndromic retinitis pigmentosa","volume":"61","author":"Martel","year":"2020","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108862_bb0920","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0925","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/IIO.0000000000000366","article-title":"Ocular inflammation and treatment emergent adverse events in retinal gene therapy","volume":"61","author":"Mehta","year":"2021","journal-title":"International Ophthalmology Clinics"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0930","first-page":"74","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: Rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0935","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.ymthe.2020.08.012","article-title":"Therapy in rhodopsin-mediated autosomal dominant retinitis pigmentosa","volume":"28","author":"Meng","year":"2020","journal-title":"Molecular Therapy\u202f: The Journal of the American Society of Gene Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb0940","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1038\/s41467-024-48092-9","article-title":"In vivo genome editing via CRISPR\/Cas9-mediated homology-independent targeted integration for Bietti crystalline corneoretinal dystrophy treatment","volume":"15","author":"Meng","year":"2024","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb0945","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","article-title":"Adeno-associated virus (AAV) cell entry: Structural insights","volume":"30","author":"Meyer","year":"2021","journal-title":"Trends in Microbiology"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108862_bb0950","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: A randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108862_bb0955","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1074\/jbc.R113.540310","article-title":"Protein splicing: How inteins escape from precursor proteins","volume":"289","author":"Mills","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb0960","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","article-title":"AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells","volume":"114","author":"Mingozzi","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108862_bb0965","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.ymthe.2021.02.013","article-title":"Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I\/IIa gene therapy trial","volume":"29","author":"Mishra","year":"2021","journal-title":"Molecular Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0970","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072224","article-title":"Targeting of the NRL pathway as a therapeutic strategy to treat retinitis pigmentosa","volume":"9","author":"Moore","year":"2020","journal-title":"Journal of Clinical Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb0975","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.ymthe.2018.04.017","article-title":"In situ gene therapy via AAV-CRISPR-Cas9-mediated targeted gene regulation","volume":"26","author":"Moreno","year":"2018","journal-title":"Molecular Therapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb0980","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/2474126420960896","article-title":"Visual acuity outcomes in patients receiving frequent treatment of neovascular age-related macular degeneration in clinical practice","volume":"5","author":"Moshfeghi","year":"2021","journal-title":"Journal of Vitreoretinal Diseases"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0985","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-62703-080-9_24","article-title":"Optimized technique for subretinal injections in mice","volume":"935","author":"M\u00fchlfriedel","year":"2013","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"key":"10.1016\/j.pharmthera.2025.108862_bb0990","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-1-4939-8669-9_26","article-title":"Optimized subretinal injection technique for gene therapy approaches","volume":"1834","author":"M\u00fchlfriedel","year":"2019","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb0995","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nbt856","article-title":"Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors","volume":"21","author":"M\u00fcller","year":"2003","journal-title":"Nature Biotechnology"},{"issue":"7988","key":"10.1016\/j.pharmthera.2025.108862_bb1000","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/d41586-023-03543-z","article-title":"First trial of 'base editing' in humans lowers cholesterol - but raises safety concerns","volume":"623","author":"Naddaf","year":"2023","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/75390","article-title":"Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors","volume":"18","author":"Nakai","year":"2000","journal-title":"Nature Biotechnology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/hum.2011.139","article-title":"Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions","volume":"23","author":"Naumer","year":"2012","journal-title":"Human Gene Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb1020","first-page":"637","article-title":"Promoter analysis of RPE65, the gene encoding a 61-kDa retinal pigment epithelium-specific protein","volume":"39","author":"Nicoletti","year":"1998","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1025","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1128\/JVI.02660-13","article-title":"Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus","volume":"88","author":"Nicolson","year":"2014","journal-title":"Journal of Virology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb1030","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/jgm.1115","article-title":"Development of photoreceptor-specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors","volume":"9","author":"Nicoud","year":"2007","journal-title":"The Journal of Gene Medicine"},{"issue":"37","key":"10.1016\/j.pharmthera.2025.108862_bb1035","doi-asserted-by":"crossref","first-page":"15012","DOI":"10.1073\/pnas.1207035109","article-title":"Retinal prosthetic strategy with the capacity to restore normal vision","volume":"109","author":"Nirenberg","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb1040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Niwa","year":"1991","journal-title":"Gene"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108862_bb1045","doi-asserted-by":"crossref","first-page":"14490","DOI":"10.1074\/jbc.R114.548255","article-title":"Enigmatic distribution, evolution, and function of inteins","volume":"289","author":"Novikova","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1050","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.64175","article-title":"scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution","volume":"10","author":"\u00d6zt\u00fcrk","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye","volume":"303","author":"Patel","year":"2019","journal-title":"Journal of Controlled Release\u202f: Official Journal of the Controlled Release Society"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108862_bb1060","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial","volume":"37","author":"Patel","year":"2023","journal-title":"Eye (London, England)"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb1065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ajhg.2021.01.006","article-title":"Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model","volume":"108","author":"Patrizi","year":"2021","journal-title":"American Journal of Human Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb1070","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013392","article-title":"Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders","volume":"13","author":"Pavlou","year":"2021","journal-title":"EMBO Molecular Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb1075","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017335","article-title":"Gene therapies for neovascular age-related macular degeneration","volume":"5","author":"Pechan","year":"2014","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108862_bb1080","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"Journal of Virology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1525-0016(03)00123-0","article-title":"In vitro selection of viral vectors with modified tropism: The adeno-associated virus display","volume":"8","author":"Perabo","year":"2003","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1090","article-title":"Epigenetic modifications and potential new treatment targets in diabetic retinopathy","volume":"2014","author":"Perrone","year":"2014","journal-title":"Journal of Ophthalmology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1095","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.ymthe.2023.06.007","article-title":"Rescue of hearing by adenine base editing in a humanized mouse model of usher syndrome type 1F","volume":"31","author":"Peters","year":"2023","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1100","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.freeradbiomed.2015.08.018","article-title":"Targeting iron-mediated retinal degeneration by local delivery of transferrin","volume":"89","author":"Picard","year":"2015","journal-title":"Free Radical Biology & Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108862_bb1105","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"7588","key":"10.1016\/j.pharmthera.2025.108862_bb1110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature16465","article-title":"An essential receptor for adeno-associated virus infection","volume":"530","author":"Pillay","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1115","doi-asserted-by":"crossref","DOI":"10.3390\/v13081526","article-title":"Designing lentiviral vectors for gene therapy of genetic diseases","volume":"13","author":"Poletti","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb1120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5114\/ceji.2016.63132","article-title":"The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy","volume":"41","author":"Po\u017carowska","year":"2016","journal-title":"Central-European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1125","first-page":"15009","article-title":"A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence","volume":"2","author":"Pryadkina","year":"2015","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1130","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1135","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220776","article-title":"Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas","volume":"220","author":"Qin","year":"2023","journal-title":"The Journal of Experimental Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb1140","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.biocel.2008.02.014","article-title":"Cell type-specific activation of the cytomegalovirus promoter by dimethylsulfoxide and 5-aza-2\u2032-deoxycytidine","volume":"40","author":"Radhakrishnan","year":"2008","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb1145","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nature Protocols"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108862_bb1150","doi-asserted-by":"crossref","first-page":"9396","DOI":"10.1128\/JVI.00209-12","article-title":"The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing","volume":"86","author":"Raupp","year":"2012","journal-title":"Journal of Virology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb1155","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","article-title":"Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec","volume":"107","author":"Reichel","year":"2023","journal-title":"The British Journal of Ophthalmology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb1160","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100050","article-title":"An optimized treatment protocol for subretinal injections limits intravitreal vector distribution","volume":"1","author":"Reichel","year":"2021","journal-title":"Ophthalmology Science"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb1165","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.ymthe.2023.10.017","article-title":"Dual AAV-based PCDH15 gene therapy achieves sustained rescue of visual function in a mouse model of Usher syndrome 1F","volume":"31","author":"Riaz","year":"2023","journal-title":"Molecular Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb1170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103643","article-title":"High-capacity adenoviral vectors: Expanding the scope of gene therapy","volume":"21","author":"Ricobaraza","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1175","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1038\/s41467-023-42386-0","article-title":"mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy","volume":"14","author":"Riedmayr","year":"2023","journal-title":"Nature Communications"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb1180","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108862_bb1185","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2016-11-751040","article-title":"Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells","volume":"129","author":"Rogers","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1190","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"7705","key":"10.1016\/j.pharmthera.2025.108862_bb1195","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41586-018-0076-4","article-title":"Restoring vision","volume":"557","author":"Roska","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108862_bb1200","doi-asserted-by":"crossref","DOI":"10.3390\/genes15060720","article-title":"Gene therapy for non-hereditary retinal disease: Age-related macular degeneration, diabetic retinopathy, and beyond","volume":"15","author":"Rowe","year":"2024","journal-title":"Genes"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1205","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: A phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108862_bb1210","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy","volume":"27","author":"Sahel","year":"2021","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1215","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"The Journal of Clinical Investigation"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1220","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/mt.2014.14","article-title":"Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy","volume":"22","author":"Sallach","year":"2014","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-62703-080-9_7","article-title":"N-methyl-D-aspartate (NMDA)-mediated excitotoxic damage: A mouse model of acute retinal ganglion cell damage","volume":"935","author":"Seitz","year":"2013","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108862_bb1230","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1021\/ja401015p","article-title":"Extein residues play an intimate role in the rate-limiting step of protein trans-splicing","volume":"135","author":"Shah","year":"2013","journal-title":"Journal of the American Chemical Society"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1235","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1039\/C3SC52951G","article-title":"Inteins: Nature\u2019s gift to protein chemists","volume":"5","author":"Shah","year":"2014","journal-title":"Chemical Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-022-01234-1","article-title":"Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration","volume":"8","author":"She","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"15\u201316","key":"10.1016\/j.pharmthera.2025.108862_bb1250","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Re: \u201cMoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by Wilson and Flotte","volume":"31","author":"Shieh","year":"2020","journal-title":"Human Gene Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb1255","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1021\/acsomega.3c00056","article-title":"Therapeutic role of ELOVL in neurological diseases","volume":"8","author":"Siddiqui","year":"2023","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb1260","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/hum.2018.118","article-title":"New MiniPromoter Ple345 (NEFL) drives strong and specific expression in retinal ganglion cells of mouse and primate retina","volume":"30","author":"Simpson","year":"2019","journal-title":"Human Gene Therapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1265","first-page":"755","article-title":"Modifier gene approach using OCU410 for dry-AMD therapy: One gene-multiple targets","volume":"64","author":"Singh","year":"2023","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-030-27378-1_7","article-title":"Long-chain polyunsaturated fatty acids and age-related macular degeneration","volume":"1185","author":"Skowronska-Krawczyk","year":"2019","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb1275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/tvst.12.11.24","article-title":"Safety and efficacy of adeno-associated viral gene therapy in patients with retinal degeneration: A systematic review and meta-analysis","volume":"12","author":"Sobh","year":"2023","journal-title":"Translational Vision Science & Technology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb1280","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/hum.2008.173","article-title":"Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing","volume":"20","author":"Song","year":"2009","journal-title":"Human Gene Therapy"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108862_bb1285","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13144227","article-title":"Summary of the therapeutic options for patients with dry and neovascular AMD","volume":"13","author":"\u015apiewak","year":"2024","journal-title":"Journal of Clinical Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1290","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/75087","article-title":"Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization","volume":"6","author":"Sun","year":"2000","journal-title":"Nature Medicine"},{"issue":"7631","key":"10.1016\/j.pharmthera.2025.108862_bb1295","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb1300","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2014.09.039","article-title":"A protein-tagging system for signal amplification in gene expression and fluorescence imaging","volume":"159","author":"Tanenbaum","year":"2014","journal-title":"Cell"},{"issue":"8023","key":"10.1016\/j.pharmthera.2025.108862_bb1305","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","article-title":"Split intein-mediated protein trans-splicing to express large dystrophins","volume":"632","author":"Tasfaout","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fimmu.2016.00037","article-title":"Ocular immune privilege and transplantation","volume":"7","author":"Taylor","year":"2016","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb1315","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: Systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1320","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/mt.2014.81","article-title":"Restoration of the majority of the visual spectrum by using modified volvox Channelrhodopsin-1","volume":"22","author":"Tomita","year":"2014","journal-title":"Molecular Therapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1325","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1167\/iovs.06-1501","article-title":"Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer","volume":"48","author":"Tomita","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1330","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/s41467-022-29550-8","article-title":"Therapeutic homology-independent targeted integration in retina and liver","volume":"13","author":"Tornabene","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1335","first-page":"448","article-title":"Inclusion of a degron reduces levelsof undesired inteins after AAV-mediated proteintrans-splicing in the retina","volume":"23","author":"Tornabene","year":"2021","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"issue":"492","key":"10.1016\/j.pharmthera.2025.108862_bb1340","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4523","article-title":"Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina","volume":"11","author":"Tornabene","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb1345","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/gt.2011.154","article-title":"Non-viral gene therapy for GDNF production in RCS rat: The crucial role of the plasmid dose","volume":"19","author":"Touchard","year":"2012","journal-title":"Gene Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb1350","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/gt.2011.78","article-title":"Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis","volume":"19","author":"Uhrig","year":"2012","journal-title":"Gene Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1355","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s42256-019-0049-9","article-title":"Leveraging implicit knowledge in neural networks for functional dissection and engineering of proteins","volume":"1","author":"Upmeier zu Belzen","year":"2019","journal-title":"Nature Machine Intelligence"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1360","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gt.2011.143","article-title":"Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors","volume":"19","author":"Varadi","year":"2012","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1365","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","article-title":"Non-syndromic retinitis pigmentosa","volume":"66","author":"Verbakel","year":"2018","journal-title":"Progress in Retinal and Eye Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb1370","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: A long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Molecular Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108862_bb1375","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Molecular Therapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb1380","article-title":"Age-related macular degeneration: Epidemiology, pathophysiology, diagnosis, and treatment","volume":"14","author":"Vyawahare","year":"2022","journal-title":"Cureus"},{"issue":"19\u201320","key":"10.1016\/j.pharmthera.2025.108862_bb1385","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1089\/hum.2021.121","article-title":"In vivo potency testing of subretinal rAAV5.hCNGB1 gene therapy in the Cngb1 knockout mouse model of retinitis Pigmentosa","volume":"32","author":"Wagner","year":"2021","journal-title":"Human Gene Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb1390","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020288","article-title":"Suprachoroidal delivery of small molecules, nanoparticles, gene and cell therapies for ocular diseases","volume":"13","author":"Wan","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1395","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1400","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1405","first-page":"1194","article-title":"Miniaturization of Usher Syndrome Type 2A gene for AAV mediated gene therapy","volume":"62","author":"Wang","year":"2021","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658399","article-title":"Anti-AAV antibodies in AAV gene therapy: Current challenges and possible solutions","volume":"12","author":"Weber","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"23","key":"10.1016\/j.pharmthera.2025.108862_bb1415","doi-asserted-by":"crossref","first-page":"9175","DOI":"10.1523\/JNEUROSCI.21-23-09175.2001","article-title":"Species-specific differences in expression of G-protein-coupled receptor kinase (GRK) 7 and GRK1 in mammalian cone photoreceptor cells: Implications for cone cell phototransduction","volume":"21","author":"Weiss","year":"2001","journal-title":"The Journal of Neuroscience\u202f: The Official Journal of the Society for Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1420","doi-asserted-by":"crossref","first-page":"21946","DOI":"10.1038\/s41598-023-49112-2","article-title":"AAV capsid bioengineering in primary human retina models","volume":"13","author":"Westhaus","year":"2023","journal-title":"Scientific Reports"},{"issue":"11\u221212","key":"10.1016\/j.pharmthera.2025.108862_bb1425","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1089\/hum.2022.222","article-title":"The degree of adeno-associated virus-induced retinal inflammation varies based on serotype and route of delivery: Intravitreal, subretinal, or suprachoroidal","volume":"34","author":"Wiley","year":"2023","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1430","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fimmu.2013.00261","article-title":"Immunology of AAV-mediated gene transfer in the eye","volume":"4","author":"Willett","year":"2013","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108862_bb1435","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"The Lancet. Global Health"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1440","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG motifs in rAAV genomes: Avoiding the toll","volume":"28","author":"Wright","year":"2020","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1445","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1038\/s41467-023-40655-6","article-title":"AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa","volume":"14","author":"Wu","year":"2023","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1450","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1455","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajo.2021.08.018","article-title":"Inhibition of complement factor 3 in geographic atrophy with NGM621: Phase 1 dose-escalation study results","volume":"235","author":"Wykoff","year":"2022","journal-title":"American Journal of Ophthalmology"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108862_bb1460","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1073\/pnas.162250899","article-title":"The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy","volume":"99","author":"Xie","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb1465","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity","volume":"116","author":"Xiong","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb1470","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1089\/hum.2004.15.896","article-title":"Trans-splicing adeno-associated viral vector-mediated gene therapy is limited by the accumulation of spliced mRNA but not by dual vector coinfection efficiency","volume":"15","author":"Xu","year":"2004","journal-title":"Human Gene Therapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108862_bb1475","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/eye.2017.158","article-title":"Technique of retinal gene therapy: Delivery of viral vector into the subretinal space","volume":"31","author":"Xue","year":"2017","journal-title":"Eye (London, England)"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108862_bb1480","article-title":"A systematic review of the neuroprotective effects of vascular endothelial growth factor (VEGF) in diabetic retinopathy and diabetic macular edema: Unraveling the molecular mechanisms and clinical implications","volume":"15","author":"Yadav","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1485","first-page":"406","article-title":"A clinically viable approach to restoring visual function using optogenetic gene therapy","volume":"29","author":"Yan","year":"2023","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"issue":"8008","key":"10.1016\/j.pharmthera.2025.108862_bb1490","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-024-07259-6","article-title":"Improving prime editing with an endogenous small RNA-binding protein","volume":"628","author":"Yan","year":"2024","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108862_bb1495","doi-asserted-by":"crossref","first-page":"9468","DOI":"10.1128\/JVI.73.11.9468-9477.1999","article-title":"Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination","volume":"73","author":"Yang","year":"1999","journal-title":"Journal of Virology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108862_bb1500","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1505","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/humc.2015.164","article-title":"Safety and biodistribution evaluation in cynomolgus macaques of rAAV2tYF-PR1.7-hCNGB3, a recombinant AAV vector for treatment of achromatopsia","volume":"27","author":"Ye","year":"2016","journal-title":"Human Gene Therapy. Clinical Development"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1510","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/hum.2015.130","article-title":"Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases","volume":"27","author":"Ye","year":"2016","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1515","first-page":"179","article-title":"Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1520","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/hum.2017.049","article-title":"Gene therapy using a miniCEP290 fragment delays photoreceptor degeneration in a mouse model of leber congenital amaurosis","volume":"29","author":"Zhang","year":"2018","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1525","doi-asserted-by":"crossref","unstructured":"Zheng, R., Zhang, L., Parvin, R., Su, L., Chi, J., Shi, K., et al. (2023). Progress and perspective of CRISPR-Cas9 technology in translational medicine. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 10(25), e2300195.","DOI":"10.1002\/advs.202300195"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108862_bb1530","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4103\/0301-4738.100542","article-title":"The worldwide epidemic of diabetic retinopathy","volume":"60","author":"Zheng","year":"2012","journal-title":"Indian Journal of Ophthalmology"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1535","series-title":"Optimal trade-off control in machine learning-based library design, with application to adeno-associated virus (AAV) for gene therapy","author":"Zhu","year":"2021"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108862_bb1540","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108862_bb1545","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2017.1324730","article-title":"Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells","volume":"6","author":"Zhu","year":"2017","journal-title":"Journal of Extracellular Vesicles"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108862_bb1550","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molmed.2022.01.003","article-title":"AAV capsid design: A Goldilocks challenge","volume":"28","author":"Zolotukhin","year":"2022","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2025.108862_bb1555","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101065","article-title":"Gene-independent therapeutic interventions to maintain and restore light sensitivity in degenerating photoreceptors","volume":"90","author":"Zuzic","year":"2022","journal-title":"Progress in Retinal and Eye Research"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:48:03Z","timestamp":1762030083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":310,"alternative-id":["S0163725825000749"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108862","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retina-directed gene therapy: Achievements and remaining challenges","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108862"}}